Compound Thalassemias and Mixed Forms

Article written and reviewed by Dr Luca Moretti

Compound thalassemias and mixed forms are a heterogeneous category of hemoglobin disorders characterized by coexistence of multiple genetic defects affecting globin-chain genes. These conditions, which are often rare and have extremely variable clinical presentations, pose major challenges in both diagnosis and genetic counseling. Their relevance lies primarily in the resulting phenotypic complexity and in the effect these combinations may have on disease severity and clinical management.

Etiology and Genetics

Mixed forms and compound thalassemias arise from the association, in the same individual, of variants affecting different globin genes or different alleles of the same globin gene. The combinations may be inherited from the parents at distinct loci or on different alleles of the same locus; more rarely, they result from complex deletions or genetic recombination events.

The main forms include:

• Compound αβ-thalassemia: simultaneous presence of a thalassemic mutation in alpha genes (HBA1/HBA2, chromosome 16) and beta genes (HBB, chromosome 11). It may occur as double heterozygosity, with one altered allele at each locus, or in more severe forms with complex homozygous/heterozygous combinations.
• αβδ-thalassemic forms: exceptionally rare associations of mutations affecting alpha, beta and delta chains, with consequent abnormalities of HbA, HbA₂ and sometimes HbF.
• Thalassemia associated with structural hemoglobinopathies: for example HbS/β-thalassemia (a form of sickle cell disease), beta-thalassemia with HbE, alpha-thalassemia with HbC, etc.
• Other complex combinations: such as thalassemia with HPFH, or mixed forms between delta-beta thalassemia and other globin abnormalities.

These combinations may result from coinheritance of variants at distinct loci, from their arrangement in cis or trans and, in some cases, from contiguous deletions or rearrangements; the inheritance pattern therefore depends on the genes involved and the allelic phase.

Pathogenesis and Pathophysiology

The pathophysiology of compound thalassemias reflects the sum and possible interaction of the molecular defects involved. Each genetic abnormality affects production of a specific globin chain, thereby modifying the proportion and quality of the different hemoglobins present in red blood cells.

In αβ-thalassemia, combined reduction of alpha and beta chains causes:

• An altered alpha-to-beta ratio, sometimes less marked than in the isolated forms, with partial compensation of the defects.
• Often more attenuated clinical and laboratory findings: microcytosis may be attenuated and, in some combinations, red blood cell indices may approach normal; anemia may be less severe than expected from either defect alone.
• HbA₂ and HbF levels that vary according to the genes involved, allelic phase and analytical method.

In mixed forms involving structural hemoglobinopathies (for example beta-thalassemia/HbS), the typical pathophysiology of each isolated disorder is modified, resulting in intermediate or sometimes more severe disease because several pathogenic processes coexist (hemolysis, red blood cell rigidity, abnormal hemoglobin precipitates, etc.).

Coinheritance may attenuate some features and worsen others. In sickle cell disease, for example, alpha-thalassemia generally reduces hemolysis and anemia, but may increase hemoglobin and viscosity and does not uniformly reduce vaso-occlusive complications.

In complex compound forms (for example αβδ-thalassemia), the hemoglobin profile is often markedly altered, with possible compensatory increases in HbF and hemoglobin variants, and clinical presentations ranging from silent forms to microcytosis associated with mild anemia.

Clinical Features

The clinical picture of compound thalassemias is extremely variable and depends on the nature, severity and combination of the defects present. In many cases, persistent hypochromic microcytosis is observed, with anemia ranging from absent to moderate. The simultaneous presence of multiple defects may result in:

• Less severe anemia than in the isolated forms because of compensatory effects, for example balanced reduction of alpha and beta chains
• Moderate chronic anemia associated with mild ineffective erythropoiesis and erythroid marrow hyperplasia
• Clinical manifestations influenced by associated structural hemoglobinopathies, for example vaso-occlusive crises when HbS coexists
• Secondary complications, including splenomegaly, jaundice and a transfusion requirement of variable frequency, up to transfusion dependence in severe combinations

In many individuals, the phenotype may be unexpectedly mild, with an abnormal blood count discovered only during family or preconception screening.

The long-term course depends on the specific combination: even double heterozygosity may produce a clinically relevant or severe phenotype, whereas other associations remain asymptomatic.

Diagnosis and Investigations

Identification of compound thalassemias requires an articulated diagnostic work-up, in which basic hematologic assessment must always be integrated with second-level investigations:

• Complete blood count and red blood cell morphology: microcytosis, hypochromia and anemia of variable degree; target cells or poikilocytosis may be present.
• Hemoglobin electrophoresis/HPLC: a variable pattern, with quantitative abnormalities of HbA, HbA₂ and HbF and possible abnormal fractions such as HbS, HbE or other variants.
• Family screening: essential to reconstruct inheritance patterns and assess the presence of multiple carriers in the same family.
• Molecular analysis: essential to identify mutations in each globin gene involved (alpha, beta, delta) by PCR, MLPA or NGS.

Particular attention must be paid to misdiagnosis: concomitant delta-thalassemia may mask beta-thalassemia in carriers, just as coexistence of alpha- and beta-thalassemia may attenuate classic findings and make it difficult to identify individuals at risk of having children with thalassemia major.

In complex cases, referral to centers specializing in hemoglobinopathies is appropriate, where advanced functional analyses, assessment of cellular HbF levels and genetic investigations for reproductive counseling can be performed.

Treatment and Prognosis

Management of compound thalassemias is based on an individualized approach that takes into account the severity of clinical presentation, the presence of complications and the overall genetic background. Mild forms do not require specific treatment, and periodic clinical surveillance and assessment of the hemoglobin profile are sufficient.

More severe forms, with significant anemia or complications associated with structural hemoglobinopathies, such as HbS/β-thalassemia, may require treatments similar to those used for major thalassemias or sickle cell disease, including transfusions, iron chelation, hydroxyurea and other therapies as appropriate.

The prognosis of compound forms is variable and depends on the specific genetic combination and clinical phenotype; correct identification of carriers remains essential for genetic counseling, in order to prevent the birth of children affected by major forms and to plan any early interventions in more complex cases.

Complications

Complications of compound thalassemias depend on the type and severity of the associated defects: they may be absent in mild forms or overlap with those of major disease in severe combinations. When structural hemoglobinopathies or major forms are present, complications may include:

• Chronic anemia and transfusion dependence
• Acute or chronic hemolysis
• Vascular complications when HbS coexists
• Iron overload
• Splenomegaly and hypersplenism

Awareness of these risks is essential for management and long-term follow-up of patients.

References
1. Bain BJ. Haemoglobinopathy diagnosis. Wiley-Blackwell. 3rd ed. 2020.
2. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge University Press. 2nd ed. 2009.
3. Old JM. Haemoglobinopathies & thalassaemias. Medicine (Abingdon). 2020;48(8):511–519.
4. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Blackwell Science. 4th ed. 2001.
5. Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013;3(2):a011684.
6. Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. Wiley-Blackwell. 7th ed. 2016.
7. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA, Cappellini MD. Non-transfusion-dependent thalassaemias. Haematologica. 2013;98(6):833–844.
8. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemias and hemoglobin E disorders. Expert Rev Hematol. 2010;3(1):103–117.
9. Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol. 1998;11(1):127–146.
10. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010;5:13.
11. Mast KJ, Hammond S, Qualman SJ, Kahwash SB. The coinheritance of β- and α-thalassemia: a review of one patient and her family. Lab Hematol. 2009;15(3):30–33. doi:10.1532/LH96.09002.
12. Vichinsky E. Hemoglobin E syndromes. Hematology Am Soc Hematol Educ Program. 2007;2007(1):79–83. doi:10.1182/asheducation-2007.1.79.
13. Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/beta-thalassaemia: a common & clinically diverse disorder. Indian J Med Res. 2011;134(4):522–531. PMID:22089616.